A cross-species drug discovery pipeline to identify and validate new treatments for osteosarcoma
J. Somarelli, G. Rupprecht, E. Altunel, E. Flamant, S. R. Rao, D. Sivaraj, A. Lazarides, S. Hoskinson, M. Sheth, S. Cheng, S. Y. Kim, K. Ware, A. Agarwal, M. Cullen, L. Selmic, , D. Hsu
This study develops a cross-species drug discovery pipeline to identify and validate new treatments for osteosarcoma, finding that dual inhibition of proteasome and CRM1 pathways induces synergistic cytotoxicity.
bioRxiv · Oct 19, 2020Cancer Biology